

Inventor : SHALABY, Shalaby Wahba
Serial No. : 09/600,648
Filed : October 17, 2000
Page : 2

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS
(Currently amended claims showing deletions by ~~striketrough~~ and
additions by underlining)

What is claimed is:

1 (currently amended): A microparticle comprising an absorbable heterochain polymer core and one or more peptide, one or more protein or a combination thereof ionically immobilized, but not conjugated, on the surface and ~~subsurface~~ crevices formed on said surface of said absorbable heterochain polymer core ~~wherein said absorbable heterochain polymer core is substantially free of said peptide, protein or combination thereof,~~

wherein each peptide is independently selected from the group consisting of growth hormone releasing peptide (GHRP), luteinizing hormone-releasing hormone (LHRH), somatostatin, bombesin, gastrin releasing peptide (GRP), calcitonin, bradykinin, galanin, melanocyte stimulating hormone (MSH), growth hormone releasing factor (GRF), amylin, tachykinins, secretin, parathyroid hormone (PTH), enkaphelin, endothelin, calcitonin gene releasing peptide (CGRP), neuromedins, parathyroid hormone related protein (PTHrP), glucagon, neurotensin, adrenocorticotrophic hormone (ACTH), peptide YY (PYY), glucagon releasing peptide (GLP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating peptide (PACAP), motilin, substance P, neuropeptide Y (NPY), TSH and analogs and fragments thereof or a pharmaceutically acceptable salt thereof; and

wherein each protein is independently selected from the group consisting of growth hormone, erythropoietin, granulocyte-colony stimulating factor, granulocyte-macrophage-colony stimulating factor and interferons; and

wherein said microparticle releases the therapeutic protein, peptide or combination thereof over an extended period of time in a patient.

2 (currently amended): A microparticle according to claim 1 wherein said peptide, protein or a combination thereof or a pharmaceutically acceptable salt thereof comprises 0.1% to 30% of the total mass of the ~~bound~~ microparticle.

3 (previously presented): A microparticle according to claim 2 wherein said absorbable heterochain polymer core comprises glycolate units.

4 (previously presented): A microparticle according to claim 3 wherein the absorbable heterochain polymer core further comprises citrate residues.

5 (previously presented): A microparticle according to claim 4 wherein the ratio of glycolate units to citrate residues is about 7-1 to about 20-1.

6 (previously presented): A microparticle according to claim 3 wherein the absorbable polymer core further comprises tartrate residues.

7 (previously presented): A microparticle according to claim 6 wherein the ratio of glycolate units to tartrate residues is about 7-1 to about 20-1.

8 (previously presented): A microparticle according to claim 3 wherein the absorbable heterochain polymer core further comprises malate residues.

9 (previously presented): A microparticle according to claim 8 wherein the ratio of glycolate units to malate residues is about 7-1 to about 20-1.

10 (previously presented): A microparticle according to claim 3 wherein said glycolate units terminate with a carboxyl moiety.

11 (previously presented): A microparticle according to claim 3 wherein said glycolate units terminate with an amine moiety.

12 (currently amended): An encased microparticle comprising one or more of a microparticle according to claim 1 encased within an absorbable encasing polymer,

wherein said microparticle comprises an absorbable heterochain polymer core and one or more peptide, one or more protein or a combination thereof immobilized on, but not conjugated to, said absorbable heterochain polymer core,

where each peptide is independently selected from the group consisting of growth hormone releasing peptide (GHRP), luteinizing hormone-releasing hormone (LHRH), somatostatin, bombesin, gastrin releasing peptide (GRP), calcitonin, bradykinin, galanin, melanocyte stimulating hormone (MSH), growth hormone releasing factor (GRF), amylin, tachykinins, secretin, parathyroid hormone (PTH), enkaphelin, endothelin, calcitonin gene releasing peptide (CGRP), neuromedins,

parathyroid hormone related protein (PTHrP), glucagon, neurotensin, adrenocorticotrophic hormone (ACTH), peptide YY (PYY), glucagon releasing peptide (GLP), vasoactive intestinal peptide (VIP), pituitary adenylate cyclase activating peptide (PACAP), motilin, substance P, neuropeptide Y (NPY), TSH and analogs and fragments thereof or a pharmaceutically acceptable salt thereof;

where each protein is independently selected from the group consisting of growth hormone, erythropoietin, granulocyte-colony stimulating factor, granulocyte-macrophage-colony stimulating factor and interferons; and where said absorbable heterochain polymer core comprises glycolate units.

13 (previously presented): An encased microparticle according to claim 12 wherein said peptide, protein or combination thereof or pharmaceutically acceptable salt thereof comprises 0.1% to 30% of the total mass of the microparticle, and where said absorbable heterochain polymer core further comprises citrate residues, tartrate residues or malate residues.

14 (original): An encased microparticle according to claim 13 wherein the ratio of glycolate units to citrate residues, tartrate residues or malate residues is about 7-1 to about 20-1 and said glycolate units terminate with a carboxyl moiety or an amine moiety.

15 (original): An encased microparticle according to claim 14 wherein said absorbable encasing polymer comprises

- (a) l-lactide based units and glycolide based units,
- (b) d,l-lactide based units and glycolide based units,
- (c) d,l-lactide based units or
- (d) l-lactide based units and d,l-lactide based units.

16 (original): An encased microparticle according to claim 15 wherein the ratio of l-lactide based units to glycolide based units is about 75-25 to about 90-10.

17 (original): An encased microparticle according to claim 15 wherein the ratio of l-lactide based units to d,l-lactide based units is about 80-20.

18 (original): An encased microparticle according to claim 15 wherein the ratio of d,l-lactide based units to glycolide based units is about 75-25 to about 90-10.

19 (original): An encased microparticle according to claim 14 wherein the absorbable encasing polymer constitutes 5 to 70% of the total mass of the encased microparticle.

20 (original): An encased microparticle according to claim 19 wherein the absorbable encasing polymer constitutes 20-60% of the total mass of the encased microparticle.

21 (original): An encased microparticle according to claim 20 wherein the absorbable encasing polymer

constitutes 30-50% of the total mass of the encased microparticle.

22 (previously presented): A pharmaceutical composition comprising the microparticles according to claim 1 and a pharmaceutically acceptable carrier.

23 (previously presented): A pharmaceutical composition comprising the microparticles according to claim 1 and a non-aqueous absorbable gel-forming liquid polyester.

24 (original): A pharmaceutical composition comprising the encased microparticles according to claim 12 and a pharmaceutically acceptable carrier.

25 (previously presented): A pharmaceutical composition comprising the encased microparticles according to claim 12 and a non-aqueous absorbable gel-forming liquid polyester.

26 (previously presented): A microparticle according to claim 4 wherein the peptide is an LHRH analog.

27 (previously presented): A microparticle according to claim 26 wherein the ratio of glycolate units to citrate residues of the absorbable heterochain polymer core is about 7-1 to about 20-1 and where the LHRH analog is p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂.

28 (previously presented): A microparticle according to claim 6 wherein the peptide is an LHRH analog.

29 (previously presented): A microparticle according to claim 28 wherein the ratio of glycolate units to tartrate

residues is about 7-1 to about 20-1 and the LHRH analog is p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂.

30 (previously presented): A microparticle according to claim 4 wherein the peptide is a somatostatin analog.

31 (previously presented): A microparticle according to claim 30 wherein the ratio of glycolate units to citrate residues is about 7-1 to about 20-1 and the somatostatin analog is H-â-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂ where the two Cys residues are bonded by a disulfide bond, N-hydroxyethylpiperazinyl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂ where the two Cys residues are bonded by a disulfide bond or N-hydroxyethylpiperazinyl-ethylsulfonyl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂ where the two Cys residues are bonded by a disulfide bond.

32 (previously presented d): A microparticle according to claim 6 wherein the peptide is a somatostatin analog.

33 (previously presented): A microparticle according to claim 32 wherein the ratio of glycolate units to tartrate residues is about 7-1 to about 20-1 and the somatostatin analog is H-â-D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂, where the two Cys residues are bonded by a disulfide bond, N-hydroxyethylpiperazinyl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂ where the two Cys residues are bonded by a disulfide bond or N-hydroxyethylpiperazinyl-ethylsulfonyl-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂ where the two Cys residues are bonded by a disulfide bond.

34 (previously presented): An encased microparticle comprising one or more microparticles according to claim 26 encased within an absorbable encasing polymer which comprises (a) l-lactide based units and glycolide based units,

(b) d,l-lactide based units and glycolide based units,

(c) d,l-lactide based units or

(d) l-lactide based units and d,l-lactide based units.

35 (original): An encased microparticle according to claim 34 wherein the ratio of glycolate units to citrate residues of the absorbable polymer core is about 7-1 to about 20-1, the LHRH analog is p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂ and where the ratio of:

(a) l-lactide based units to glycolide based units is about 75-25 to about 90-10,

(b) d,l-lactide based units to glycolide based units is about 75-25 to about 90-10 and

(c) l-lactide based units to d,l-lactide based units is about 80-20.

36 (previously presented): An encased microparticle comprising one or more microparticles according to claim 28 encased within an absorbable encasing polymer which comprises (a) l-lactide based units and glycolide based units,

(b) d,l-lactide based units and glycolide based units,

(c) d,l-lactide based units or

(d) l-lactide based units and d,l-lactide based units.

37 (original): An encased microparticle according to claim 36 wherein the ratio of glycolate units to tartrate residues of the absorbable polymer core is about 7-1 to about 20-1, the LHRH analog is p-Glu-His-Trp-Ser-Tyr-D-Trp-Leu-Arg-Pro-Gly-NH₂ and where the ratio of:

(a) l-lactide based units to glycolide based units is about 75-25 to about 90-10,

(b) d,l-lactide based units to glycolide based units is about 75-25 to about 90-10 and

(c) l-lactide based units to d,l-lactide based units is about 80-20.

38 (previously presented): An encased microparticle comprising one or more microparticles according to claim 30 encased within an absorbable encasing polymer which comprises

(a) l-lactide based units and glycolide based units,

(b) d,l-lactide based units and glycolide based units,

(c) d,l-lactide based units or

(d) l-lactide based units and d,l-lactide based units.

39 (original): An encased microparticle according to claim 38 wherein the ratio of glycolate units to citrate residues of the absorbable polymer core is about 7-1 to about 20-1, the somatostatin analog is H- α -D-Nal-Cys-Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂ where the two Cys residues are bonded by a disulfide bond, N-hydroxyethylpiperazinyl-acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂ where the two Cys residues are bonded by a disulfide bond or N-

hydroxyethylpiperazinyl-ethylsulfonyl-Phe-Cys-Tyr-D-Trp-Lys-
Abu-Cys-Thr-NH₂ where the two Cys residues are bonded by a
disulfide bond;

and where the ratio of:

(a) l-lactide based units to glycolide based units is about
75-25 to about 90-10,

(b) d,l-lactide based units to glycolide based units is
about 75-25 to about 90-10 and

(c) l-lactide based units to d,l-lactide based units is
about 80-20.

40 (previously presented): An encased microparticle
comprising one or more microparticles according to claim 32
and an absorbable encasing polymer which comprises

(a) l-lactide based units and glycolide based units,

(b) d,l-lactide based units and glycolide based units,

(c) d,l-lactide based units or

(d) l-lactide based units and d,l-lactide based units.

41 (original): An encased microparticle
according to claim 40 wherein the ratio of glycolate units
to tartrate residues of the absorbable polymer core is about
7-1 to about 20-1, the somatostatin analog is H-â-D-Nal-Cys-
Tyr-D-Trp-Lys-Val-Cys-Thr-NH₂ where the two Cys residues are
bonded by a disulfide bond, N-hydroxyethylpiperazinyl-
acetyl-D-Phe-Cys-Tyr-D-Trp-Lys-Abu-Cys-Thr-NH₂ where the two
Cys residues are bonded by a disulfide bond or N-
hydroxyethylpiperazinyl-ethylsulfonyl-Phe-Cys-Tyr-D-Trp-Lys-

Inventor : SHALABY, Shalaby Wahba
Serial No. : 09/600,648
Filed : October 17, 2000
Page : 12

Abu-Cys-Thr-NH₂, where the two Cys residues are bonded by a disulfide bond;

and where the ratio of:

(a) l-lactide based units to glycolide based units is about 75-25 to about 90-10,

(b) d,l-lactide based units to glycolide based units is about 75-25 to about 90-10 and

(c) l-lactide based units to d,l-lactide based units is about 80-20.

42 (previously presented): A process for making an encased microparticle according to claim 12 comprising the step of encasing a microparticle with an absorbable encasing polymer.

43 (previously presented): A process according to claim 42 wherein a dispersion of said microparticles in a solution comprising said absorbable encasing polymer and a solvent is dropped onto a pre-cooled medium, where said medium is not a solvent of said absorbable encasing polymer.

44 (original): A process according to claim 43 wherein the solution of the absorbable encasing polymer consists of about 5% to 30% of the absorbable encasing polymer, the pre-cooled medium is an alcohol having two or more carbon atoms and the temperature of the medium is room temperature to about -80°C.

45 (original): A process according to claim 44 wherein the temperature of the pre-cooled medium is about -60°C to -80°C and the medium is isopropyl alcohol.

46 (previously presented): A process for making an encased microparticle according to claim 12 comprising the step of encasing the microparticle with an absorbable encasing polymer using an emulsion technique.

47 (previously presented): A pharmaceutical composition according to claim 23 which further comprises a pharmaceutically acceptable carrier.

48 (previously presented): A pharmaceutical composition according to claim 25 which further comprises a pharmaceutically acceptable carrier.